DUNDR, Pavel, Michaela BÁRTŮ, Tjalling BOSSE, Quang Hiep BUI, David CIBULA, Jana DROZENOVÁ, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan HOJNÝ, Nikola HÁJKOVÁ, Radek JAKŠA, Jan LACO, Sigurd F. LAX, Radoslav MATĚJ, Gábor MÉHES, Romana MICHÁLKOVÁ, Adam ŠAFANDA, Kristýna NĚMEJCOVÁ, Naveena SINGH, Simona STOLNICU, Marián ŠVAJDLER, Tomáš ZIMA, Ivana STRUŽINSKÁ and W Glenn MCCLUGGAGE. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories. Modern Pathology. NEW YORK: ELSEVIER SCIENCE INC, 2023, vol. 36, No 1, p. 1-14. ISSN 0893-3952. Available from: https://dx.doi.org/10.1016/j.modpat.2022.100040.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories
Authors DUNDR, Pavel (203 Czech Republic, guarantor), Michaela BÁRTŮ (203 Czech Republic), Tjalling BOSSE, Quang Hiep BUI, David CIBULA (203 Czech Republic), Jana DROZENOVÁ (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Oluwole FADARE, Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Jan HOJNÝ (203 Czech Republic), Nikola HÁJKOVÁ (203 Czech Republic), Radek JAKŠA (203 Czech Republic), Jan LACO (203 Czech Republic), Sigurd F. LAX, Radoslav MATĚJ (203 Czech Republic), Gábor MÉHES, Romana MICHÁLKOVÁ (203 Czech Republic), Adam ŠAFANDA (203 Czech Republic), Kristýna NĚMEJCOVÁ (203 Czech Republic), Naveena SINGH, Simona STOLNICU, Marián ŠVAJDLER (203 Czech Republic), Tomáš ZIMA (203 Czech Republic), Ivana STRUŽINSKÁ (203 Czech Republic) and W Glenn MCCLUGGAGE.
Edition Modern Pathology, NEW YORK, ELSEVIER SCIENCE INC, 2023, 0893-3952.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30109 Pathology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.500 in 2022
RIV identification code RIV/00216224:14110/23:00130743
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.modpat.2022.100040
UT WoS 000982550100001
Keywords in English borderline; diagnostic agreement; mucinous tumors; next-generation sequencing; ovary; therapeutic targets
Tags 14110230, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/7/2023 10:41.
Abstract
Primary ovarian mucinous tumors represent a heterogeneous group of neoplasms, and their diagnosis may be challenging. We analyzed 124 primary ovarian mucinous tumors originally diagnosed as mucinous borderline tumors (MBTs) or mucinous carcinomas (MCs), with an emphasis on interobserver diagnostic agreement and the potential for diagnostic support by molecular profiling using a next-generation sequencing targeted panel of 727 DNA and 147 RNA genes. Fourteen experienced pathologists independently assigned a diagnosis from preset options, based on a review of a single digitized slide from each tumor. After excluding 1 outlier participant, there was a moderate agreement in diagnosing the 124 cases when divided into 3 categories (κ = 0.524, for mucinous cystadenoma vs MBT vs MC). A perfect agreement for the distinction between mucinous cystadenoma/MBT as a combined category and MC was found in only 36.3% of the cases. Differentiating between MBTs and MCs with expansile invasion was particularly problematic. After a reclassification of the tumors into near-consensus diagnostic categories on the basis of the initial participant results, a comparison of molecular findings between the MBT and MC groups did not show major and unequivocal differences between MBTs and MCs or between MCs with expansile vs infiltrative pattern of invasion. In contrast, HER2 overexpression or amplification was found only in 5.3% of MBTs and in 35.3% of all MCs and in 45% of MCs with expansile invasion. Overall, HER2 alterations, including mutations, were found in 42.2% of MCs. KRAS mutations were found in 65.5% and PIK3CA mutations in 6% of MCs. In summary, although the diagnostic criteria are well-described, diagnostic agreement among our large group of experienced gynecologic pathologists was only moderate. Diagnostic categories showed a molecular overlap. Nonetheless, molecular profiling may prove to be therapeutically beneficial in advanced-stage, recurrent, or metastatic MCs.
Links
90125, large research infrastructuresName: BBMRI-CZ III
PrintDisplayed: 28/7/2024 23:23